ARTIMPLANT INTERIM REPORT JANUARY - SEPTEMBER 2010

ARTIMPLANT INTERIM REPORT JANUARY - SEPTEMBER 2010

Västra Frölunda, Sweden, October 28, 2010


  · Net revenue for the third quarter amounted to SEK 5.1 million (5.5)
and for January-September SEK 14.9 million (18.2).*
  · The net loss for the third quarter totaled SEK 5.2 million (4.7) and
for January-September SEK 15.0 million (13.2).  
  · Earnings per stock unit for the third quarter amounted to SEK -0.09
(-0.08) and for January-September SEK -0.25 (-0.22).
  · Artimplant's own sales continued to increase and were equivalent to
65% (40) of product sales for the third quarter and 59% (30) for
January-September.
  · Artimplant's own sales in the USA have tripled at the same time that
revenue from license sales halved compared with January-September 2009.
  · Artimplant's strategy has been focused on marketing with increased
intensity in own sales in the USA.
  · Artimplant has implemented staff cutbacks equivalent to an annual
saving of approximately SEK 5 million once the periods of notice have
come to an end.
  · Study data has been presented which supports the use of Artelon® in
a number of treatment applications.

 Events after the period-end

  · Artimplant's rights issue was oversubscribed by 89% and, as planned,
has generated capital input for the Company of approximately SEK 38.5
million before issue costs.
  · The issue will increase the number of Series B stocks by 59,244,790,
from 58,669,790 to 117,914,580. The number of Series A stocks remains
unchanged at 575,000. The total number of stocks after the issue is thus
118,489,580.
  · The total number of votes following the issue is 123,664,580.

 

N. B. This is a translation from Swedish. The Swedish version shall
always take precedence.

Artimplant will hold a telephone conference by reason of this report on
October 28, 2010 at 11 am (CET). For further information see
www.artimplant.com.

* Figures in brackets refer to the corresponding period last year

For further information, please contact: Hans Rosén, CEO, phone 46
(0)31-746 56 00, 46 (0)708 58 34 70,
hans.rosen@artimplant.com (hans.rosen@artimplant.com)

Lars-Johan Cederbrant, CFO, phone 46 (0)31-746 56 54, 46 (0)703 01 68
54,
lars-johan.cederbrant@artimplant.com (lars-johan.cederbrant@artimplant.c
om)

Further information is available at
www.artimplant.com (http://www.artimplant.com). To subscribe to future
press releases please go to
www.artimplant.com/investors-media/subscribe-to-press-releases.html (htt
p://www.artimplant.com/investors-media/subscribe-to-press-releases.html)